ArticleJAMA network open2025

Adjuvant Chemotherapy Use for Hormone Receptor-Positive, ERBB2-Negative Breast Cancer After RxPONDER Trial.

Jincong Q Freeman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.